Efficacy and safety of house dust mite subcutaneous immunotherapy in polysensitized children with allergic asthma

Zhang, Panpan; Jia, Yuanyuan; Jing, Zenghui; Huang, Jiehong; Wu, Huajie; Sun, Xin

doi:10.1016/j.pupt.2022.102187

Cited by 3 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings indicate that a 3-year course of SCIT has the potential to decrease both day-time and night-time asthmatic symptom scores, improve peak expiratory flow (PEF) values, lower serum IgE levels, and most notably, reduce the requirement of inhaled corticosteroids (ICSs). Zhang et al conducted a study in which they recruited 51 children with allergic asthma to compare the effectiveness and safety of long-term HDM-SCIT in mono- and polysensitized children ( 63 ). In terms of clinical effectiveness and safety of HDM-SCIT, there was no significant difference between mono-sensitized and poly-sensitized children with allergic asthma.…”

Section: Ait In Chinamentioning

confidence: 99%

Allergen immunotherapy in China

Yang,

Li,

Zhu

2024

Front. Allergy

View full text Add to dashboard Cite

Allergen immunotherapy (AIT) is an etiological treatment strategy that involves administering escalating doses of clinically relevant allergens to desensitize the immune system. It has shown encouraging results in reducing allergy symptoms and enhancing patients' quality of life. In this review, we offer a thorough overview of AIT in China, examining its efficacy, safety, current practices, and prospects. We further underscore the progress made in AIT research and clinical applications, as well as the distinct challenges and opportunities that China faces in this area.

show abstract

Section: Ait In Chinamentioning

confidence: 99%

Allergen immunotherapy in China

Yang,

Li,

Zhu

2024

Front. Allergy

View full text Add to dashboard Cite

show abstract

A Novel Dose-Adjustment Protocol for Interrupted Subcutaneous Immunotherapy for Allergic Rhinitis

Feng

Liu

2023

Immunotherapy

View full text Add to dashboard Cite

Background: This study aimed to develop a novel dose strategy for subcutaneous immunotherapy to reduce medical waste and financial burdens for patients who are required to restart subcutaneous immunotherapy. Patients & methods: A prospective, nonrandomized concurrent controlled trial was performed to assess the safety and advantages of the novel dose-adjustment protocol compared with the conventional one. 76 subjects were grouped to receive novel or conventional dose-adjustment protocols. Results: The injections, visits and time needed to reach the pre-established dose with the novel regimen were decreased. Furthermore, there were no differences in side reactions between the two groups. Conclusion: The novel protocol seemed safe and well tolerated, offering the advantages of time efficiency and reduced healthcare costs.

show abstract

House dust mite allergy – Management

Kathuria,

Rai

2024

Indian Journal of Allergy, Asthma and Immunology

View full text Add to dashboard Cite

Allergen vulnerability is highly individual specific. House dust mites (HDMs) are major sources of airborne allergens, found not only in houses but also detected in workplaces and most schools. The two most common HDM species from the Pyroglyphidae family, namely Dermatophagoides pteronyssinus and Dermatophagoides farinae are responsible for 90% of sensitization and allergic symptoms. Clinical conditions due to HDM allergen are rhinitis, conjunctivitis, asthma and/or atopic dermatitis (AD), and rare severe systemic reaction. Accurate diagnosis by skin prick test, specific immunoglobulin E (extract and component-based), or nasal provocation test with standardized HDM extract in contest with clinically relevant exposure to dust mites is fundamental for successful treatment. Allergen immunotherapy (AIT) is the only treatment providing sustained efficacy for moderate-to-severe allergic rhinitis, allergic asthma, and AD. This review will mainly focus on the description of HDM allergens, immunology, efficacy, and HDM-AIT (subcutaneous immunotherapy and sublingual immunotherapy).

show abstract

Efficacy and safety of house dust mite subcutaneous immunotherapy in polysensitized children with allergic asthma

Cited by 3 publications

References 36 publications

Allergen immunotherapy in China

Allergen immunotherapy in China

A Novel Dose-Adjustment Protocol for Interrupted Subcutaneous Immunotherapy for Allergic Rhinitis

House dust mite allergy – Management

Contact Info

Product

Resources

About